The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.本發明涉及盧梭利替尼或其藥學上可接受的鹽之緩釋性調配物和劑型,它們可用於治療傑納斯激酶相關疾病,如骨髓增生性病症。